Back to All
April 4, 2023

PyrAmes selected for NIH RADx Tech for Maternal Health Challenge final phase

PyrAmes is among only 10 companies chosen to enter the final Technology Assessment phase of the National Institutes of Health (NIH) RADx Tech for Maternal Health Challenge. The goal of the RADx Challenge is to improve maternal health outcomes for those who live in areas lacking access to maternity care through innovative promising home-based or point-of-care diagnostic devices, wearables, and other remote sensing technologies.

PyrAmes’ submission, Non-invasive, Continuous Blood Pressure Monitoring for Postpartum Maternal Health, focuses on its Bosimi™ platform, a noninvasive, wearable sensor designed to monitor blood pressure of women in their postpartum period, when the risk of maternal mortality is highest.

For high-risk pregnancies, it is advised to frequently monitor new mothers to obtain important BP trend information potentially indicating the onset of an adverse event. Bosimi is designed to enable more frequent blood pressure monitoring than current standards of care, potentially resulting in better control of blood pressure and timely treatment if adverse events are detected.

During the final RADx Technology Assessment phase, PyrAmes will work its NIH team to accelerate development of Bosimi, by leveraging NIH support to overcome technological, clinical, usability, regulatory, and commercialization hurdles.

“We’re excited to continue working with our NIH RADx team through the end of this year and into 2024 to accelerate Bosimi development for critical postpartum maternal health needs,” said Xina Quan, Ph.D., PyrAmes CEO and Co-founder. “The prospect of providing greater access for postpartum women to more effective blood pressure monitoring in the critical weeks after birth is wonderful opportunity,” she indicated.

NIH RADx received more than 80 submissions for the RADx Challenge’s initial Viability Assessment phase, with 15 companies advancing to the follow-on Deep Dive phase. Proposals were evaluated against a rigorous set of scientific, technical, regulatory, clinical, and commercialization requirements.